AI Portfolio Summary
In 2025 Q4, GordonMD Global Investments LP maintained a portfolio of 13 distinct positions. The most significant new addition to the portfolio was KYVERNA THERAPEUTICS, which now represents 29.60% of the total fund value.
Total Positions
13
Quarter
2025 Q4
Top Holding
KYTX (29.6%)
Top 10 Concentration
89.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-13 of 13
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KYTX
KYVERNA THERAPE...
|
Healthcare | 29.60% | — |
#1
Prev: #—
|
9.5 | 4,391,818 | no change |
NEW
|
4,391,818 | $41,283,089 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 17.22% | — |
#2
Prev: #—
|
9.0 | 769,550 | no change |
NEW
|
769,550 | $24,017,656 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BLCO
BAUSCH PLUS LOM...
|
Healthcare | 7.51% | — |
#3
Prev: #—
|
7.5 | 613,472 | no change |
NEW
|
613,472 | $10,478,102 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 7.48% | — |
#4
Prev: #—
|
7.0 | 224,135 | no change |
NEW
|
224,135 | $10,433,484 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMGN
AMGEN INC
|
Healthcare | 5.45% | — |
#5
Prev: #—
|
6.2 | 23,212 | no change |
NEW
|
23,212 | $7,597,520 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 5.43% | — |
#6
Prev: #—
|
5.7 | 329,101 | no change |
NEW
|
329,101 | $7,569,323 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 5.25% | — |
#7
Prev: #—
|
5.6 | 1,330,901 | no change |
NEW
|
1,330,901 | $7,319,956 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VIR
VIR BIOTECHNOLO...
|
Healthcare | 4.02% | — |
#8
Prev: #—
|
5.1 | 930,317 | no change |
NEW
|
930,317 | $5,609,812 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 3.91% | — |
#9
Prev: #—
|
5.1 | 66,680 | no change |
NEW
|
66,680 | $5,459,758 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INCY
INCYTE CORP
|
Healthcare | 3.86% | — |
#10
Prev: #—
|
5.0 | 54,500 | no change |
NEW
|
54,500 | $5,382,965 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
INSMED INC
|
Healthcare | 3.57% | — |
#11
Prev: #—
|
4.9 | 28,587 | no change |
NEW
|
28,587 | $4,975,281 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PYXS
PYXIS ONCOLOGY ...
|
Healthcare | 3.40% | — |
#12
Prev: #—
|
4.9 | 4,121,870 | no change |
NEW
|
4,121,870 | $4,740,151 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 3.32% | — |
#13
Prev: #—
|
4.8 | 170,307 | no change |
NEW
|
170,307 | $4,625,538 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-13 of 13 holdings